Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21908576 | 0.90 | KDM4E (0.38) | KDM4EGAAL3MBTL1MAOBMEN1 | |
| SCHEMBL20151064 | 0.81 | GAA (0.31) | KDM4EGAAL3MBTL1MAOBMEN1 | |
| SCHEMBL20150967 | 0.81 | GAA (0.35) | KDM4EGAAL3MBTL1MAOBMEN1 | |
| SCHEMBL21908577 | 0.77 | L3MBTL1 (0.38) | KDM4EGAAL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL20150963 | 0.76 | POLB (0.57) | KDM4EMAOBMEN1KMT2A | |
| SCHEMBL20150962 | 0.75 | POLB (0.37) | KDM4EGAAL3MBTL1MAOBMEN1 | |
| SCHEMBL20150970 | 0.74 | KDM4E (0.33) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL20151073 | 0.74 | MAPT (0.46) | KDM4EGAAMEN1ALDH1A1MAPT | |
| SCHEMBL20150971 | 0.72 | CTH (0.32) | — | |
| SCHEMBL20150968 | 0.72 | CTH (0.40) | KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067860-A1 | COMPOSITIONS AND METHODS FOR CARBON DIOXIDE SOLIDIFICATION | CHEVRON U.S.A. INC. | 2024-02-29 | — | — | US | disclosed |
| US-10633332-B2 | Guanidine compounds for removal of oxyanions from aqueous solutions and for carbon dioxide capture | UT-BATTELLE, LLC (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180134655-A1 | GUANIDINE COMPOUNDS FOR REMOVAL OF OXYANIONS FROM AQUEOUS SOLUTIONS AND FOR CARBON DIOXIDE CAPTURE | U.S. DEPARTMENT OF ENERGY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633332-B2 | Guanidine compounds for removal of oxyanions from aqueous solutions and for carbon dioxide capture | GUCY1A1, GUCY1A2, GUCY1B1 | KDM4E 1102/4885GAA 655/4885L3MBTL1 2462/4885 |
| US-20180134655-A1 | GUANIDINE COMPOUNDS FOR REMOVAL OF OXYANIONS FROM AQUEOUS SOLUTIONS AND FOR CARBON DIOXIDE CAPTURE | GUCY1A1, GUCY1A2, GUCY1B1 | KDM4E 1102/4885GAA 655/4885L3MBTL1 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.